1-3 of 3
Sharon Chen
Close
Sort by
Journal Articles

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Varsha Sundaresan, Brigitte Senechal, Xiuyan Wang, Shubhra Kashyap, Erica Tong, Adarsh Joshi, Ajeeta Dash, Leopold Sellner, Sharon Chen, Devin McAvoy, Kinga K Hosszu, Devanjan S Sikder, Isabelle Riviere, Michel Sadelain, Jae H. Park, Reshma Singh
Journal: Blood
Blood (2023) 142 (Supplement 1): 349.
https://doi.org/10.1182/blood-2023-177712
Published: 2023
Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H Park, M. Lia Palomba, Isabelle Rivière, Devanjan S. Sikder, Brigitte Senechal, Xiuyan Wang, Vladimir P. Bermudez, Elizabeth R. Cathcart, Kelly Liotta, Jannakie Joseph, Jia Li, Yunqi Zhao, Rachael Liu, Sharon Chen, Leopold Sellner, Michel Sadelain
Journal: Blood
Blood (2022) 140 (Supplement 1): 403–404.
https://doi.org/10.1182/blood-2022-168206
Published: 2022
Journal Articles

The Identification and Use of a Three Fungus-Antigen Combination to Generate T-Cell Products with Activity Against Pathogenic Filamentous Fungi and Yeasts for Clinical Cell Therapy

Shiva Deo, BSc PhD, Balaji Virassamy, M. Biotech, Catriona Halliday, PhD, Leighton Edward Clancy, PhD, Wieland Meyer, PhD, Sharon Chen, MB BS FRACP FRCPA PhD, Tania Sorrell, MB BS PhDFRACP FRCPA, David Gottlieb, MB MDFRCPA FRACP
Journal: Blood
Blood (2014) 124 (21): 3839.
https://doi.org/10.1182/blood.V124.21.3839.3839
Published: 2014